The promise of KCa3.1 as a therapeutic target for AD is further strengthened by the observations that KCa3.1 blockers are very mild immunosuppressants that do not reduce the ability of rodents to clear viral infections like flu [47]. The gene discussed is KCNN4; the disease is viral infectious disease.